Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18738385 | STRAIN OF SELENIUM-ENRICHED LACTIPLANTIBACILLUS PLANTARUM KD-2 AND APPLICATIONS IN PREPARING FERMENTED GOAT MILK AND GOAT MILK POWDER | June 2024 | April 2025 | Allow | 10 | 1 | 1 | No | No |
| 18663247 | CAMELIDAE SINGLE-DOMAIN ANTIBODIES AGAINST YERSINIA PESTIS AND METHODS OF USE | May 2024 | May 2025 | Allow | 12 | 1 | 1 | No | No |
| 18609152 | METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONS | March 2024 | May 2025 | Allow | 14 | 1 | 0 | No | No |
| 18591306 | Prevotella Copri Compositions | February 2024 | April 2025 | Allow | 13 | 1 | 0 | No | No |
| 18584070 | METHOD FOR EX-VIVO EXPANSION OF REGULATORY T CELLS WITH ENHANCED SUPPRESSIVE FUNCTION FOR CLINICAL APPLICATION IN IMMUNE MEDIATED DISEASES | February 2024 | May 2025 | Allow | 15 | 2 | 0 | No | No |
| 18407367 | IMMUNOGENIC COMPOSITIONS COMPRISING MYCOBACTERIUM TUBERCULOSIS POLYPEPTIDES AND FUSIONS THEREOF | January 2024 | February 2025 | Allow | 14 | 1 | 1 | No | No |
| 18392708 | COMPOSITION FOR SUPPRESSING OR IMPROVING EYE FATIGUE | December 2023 | June 2025 | Allow | 18 | 2 | 1 | No | No |
| 18470301 | SYNTHETIC PLASMODIUM ANTIGENS, COMPOSITIONS, AND USES THEREOF | September 2023 | March 2025 | Allow | 18 | 2 | 1 | No | No |
| 18364104 | NEUTRALIZING ANTIBODIES TO PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN AND THEIR USE | August 2023 | September 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18361084 | METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONS | July 2023 | August 2024 | Abandon | 12 | 2 | 0 | No | No |
| 18361724 | CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO | July 2023 | November 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18328162 | MODIFIED MENINGOCOCCAL FHBP POLYPEPTIDES | June 2023 | January 2025 | Allow | 20 | 1 | 1 | No | No |
| 18300049 | MICROBIOTA COMPOSITION, AS A MARKER OF RESPONSIVENESS TO ANTI-PD1/PD-L1/PD-L2 ANTIBODIES AND USE OF MICROBIAL MODULATORS FOR IMPROVING THE EFFICACY OF AN ANTI-PD1/PD-L1/PD-L2 AB-BASED TREATMENT | April 2023 | July 2024 | Allow | 15 | 1 | 1 | No | No |
| 18131560 | CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO | April 2023 | September 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18193151 | INSECTICIDAL POLYPEPTIDES HAVING IMPROVED ACTIVITY SPECTRUM AND USES THEREOF | March 2023 | April 2025 | Allow | 24 | 2 | 1 | No | No |
| 18173288 | BIOMARKERS AND IMMUNOGENIC COMPOSITIONS FOR FILARIAL PARASITES | February 2023 | January 2025 | Allow | 23 | 1 | 1 | Yes | No |
| 18090413 | FECAL FUNGOME AND THERAPEUTIC EFFICACY OF FECAL MICROBIOTA TRANSPLANTATION | December 2022 | June 2025 | Allow | 29 | 2 | 0 | No | No |
| 17993329 | COMPOSITIONS AND METHODS FOR TREATING SKIN INFECTIONS AND OTHER DISEASES | November 2022 | May 2025 | Abandon | 30 | 2 | 1 | No | No |
| 17993310 | Pet Food Compositions Including Probiotics and Methods of Manufacture and Use Thereof | November 2022 | June 2025 | Allow | 30 | 2 | 0 | No | No |
| 17986424 | METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONS | November 2022 | June 2023 | Allow | 7 | 1 | 0 | No | No |
| 18047477 | Novel Bifidobacterium Genus Bacterium | October 2022 | June 2024 | Allow | 20 | 1 | 1 | Yes | No |
| 17995004 | NOVEL USE OF BCG IMMUNOGENIC FORMULATION EXPRESSING A HUMAN RESPIRATORY SYNCYTIAL VIRUS PROTEIN AGAINST bRSV IN CATTLE | September 2022 | November 2023 | Abandon | 14 | 1 | 0 | No | No |
| 17881131 | METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONS | August 2022 | October 2022 | Allow | 2 | 0 | 0 | No | No |
| 17861587 | DERMAL FILLER | July 2022 | December 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17862269 | TREATMENTS OF CANCER USING NITROUS OXIDE AND BOTULINIUM TOXIN | July 2022 | January 2025 | Allow | 30 | 2 | 1 | Yes | No |
| 17838698 | COMPOSITION FOR SUPPRESSING OR IMPROVING EYE FATIGUE | June 2022 | September 2023 | Allow | 15 | 2 | 0 | Yes | No |
| 17834865 | PROTEIN ANTIGENS THAT PROVIDE PROTECTION AGAINST PNEUMOCOCCAL COLONIZATION AND/OR DISEASE | June 2022 | May 2024 | Allow | 23 | 1 | 1 | Yes | No |
| 17833962 | COMPOSITIONS COMPRISING BACTERIAL STRAINS | June 2022 | November 2023 | Abandon | 17 | 1 | 0 | No | No |
| 17731106 | METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONS | April 2022 | July 2022 | Allow | 3 | 0 | 0 | No | No |
| 17711257 | Strain of Lactobacillus rhamnosus and Application thereof in Inhibiting Helicobacter pylori | April 2022 | January 2025 | Allow | 34 | 1 | 1 | No | No |
| 17764498 | PSEUDOMONAS ISOLATES AND USES THEREOF | March 2022 | March 2025 | Allow | 36 | 1 | 0 | No | No |
| 17703790 | IMMUNOGENIC FUSION PROTEIN | March 2022 | August 2024 | Allow | 29 | 2 | 1 | No | No |
| 17692333 | TOXOPLASMA GONDII VACCINES AND THEIR USE | March 2022 | January 2024 | Allow | 22 | 1 | 1 | No | No |
| 17641315 | ANTIGEN BINDING PROTEIN AND ASSAYS | March 2022 | March 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17638321 | METHODS OF INCREASING VACCINE EFFICACY | February 2022 | March 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17638190 | FISH SKIN MICROBIOME | February 2022 | January 2025 | Abandon | 35 | 0 | 1 | No | No |
| 17636743 | IMMUNOLOGICALLY ACTIVE FRAGMENTS OF TOXOPLASMA GONDII | February 2022 | August 2024 | Allow | 30 | 3 | 1 | No | No |
| 17651033 | COMPOSITIONS AND METHODS FOR PROMOTING NITRIC OXIDE PRODUCTION THROUGH AN ORAL DELIVERY SYSTEM | February 2022 | January 2025 | Abandon | 35 | 0 | 1 | No | No |
| 17633791 | TEST SYSTEM FOR RECOGNIZING LEGIONELLAE | February 2022 | January 2025 | Abandon | 35 | 0 | 1 | No | No |
| 17629269 | IN VITRO METHOD FOR DISCRIMINATING LATENT FROM ACTIVE TUBERCULOSIS | January 2022 | January 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17571079 | NOVEL IMMUNOGENS AND METHODS FOR DISCOVERY AND SCREENING THEREOF | January 2022 | March 2025 | Allow | 38 | 2 | 1 | No | No |
| 17597051 | COMPOSITIONS COMPRISING SECRETORY IgA AND PROBIOTICS | December 2021 | April 2025 | Allow | 40 | 2 | 1 | No | No |
| 17558418 | CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO | December 2021 | August 2023 | Abandon | 20 | 2 | 0 | No | No |
| 17554354 | PNEUMOCOCCAL CONJUGATE VACCINE FORMULATIONS | December 2021 | May 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17548904 | AGENT FOR INDUCING INTERFERON PRODUCTION CONTAINING LACTIC ACID BACTERIA | December 2021 | December 2023 | Allow | 24 | 1 | 1 | No | No |
| 17545148 | PROBIOTIC BIFIDOBACTERIUM STRAIN | December 2021 | September 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17541546 | DERMAL FILLER | December 2021 | December 2024 | Abandon | 36 | 1 | 0 | No | No |
| 17533320 | ANTI-INFLAMMATORY COMPOUNDS AND METHODS OF USE | November 2021 | August 2024 | Allow | 33 | 2 | 1 | Yes | No |
| 17532034 | Proteins and nucleic acids useful in vaccines targeting pseudomonas aeruginosa | November 2021 | November 2023 | Allow | 24 | 1 | 0 | No | No |
| 17515985 | METHOD FOR EX-VIVO EXPANSION OF REGULATORY T CELLS WITH ENHANCED SUPPRESSIVE FUNCTION FOR CLINICAL APPLICATION IN IMMUNE MEDIATED DISEASES | November 2021 | June 2024 | Abandon | 32 | 2 | 1 | No | No |
| 17502259 | Penicillium oxalicum SDF-25 strain and application thereof | October 2021 | March 2025 | Allow | 41 | 1 | 1 | No | No |
| 17497157 | ANTIBODY MOLECULE-DRUG CONJUGATES AND USES THEREOF | October 2021 | April 2025 | Abandon | 42 | 3 | 1 | No | No |
| 17491889 | COMBINATIONS OF ANTI-STAPHYLOCOCCUS AUREUS ANTIBODIES | October 2021 | January 2024 | Abandon | 28 | 1 | 1 | No | No |
| 17483162 | ANTIBODY DIRECTED AGAINST S. AUREUS CLUMPING FACTOR A (ClfA) | September 2021 | December 2023 | Allow | 27 | 1 | 1 | No | No |
| 17459715 | HELICOBACTER THERAPEUTIC | August 2021 | July 2023 | Allow | 22 | 1 | 0 | No | No |
| 17430117 | COMPOSITIONS AND METHODS FOR USING BISPECIFIC ANTIBODIES TO BIND COMPLEMENT AND A TARGET ANTIGEN | August 2021 | June 2025 | Allow | 47 | 2 | 1 | No | No |
| 17377475 | ROS KINASE IN LUNG CANCER | July 2021 | February 2024 | Abandon | 31 | 1 | 1 | No | No |
| 17253798 | Vaccine Used For Preventing Toxoplasma Gondii Infection And Preparation Method Therefor | July 2021 | September 2022 | Allow | 21 | 2 | 1 | No | No |
| 17309996 | NANOVESICLES DERIVED FROM BACTERIA OF GENUS DEINOCOCCUS, AND USE THEREOF | July 2021 | January 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17368396 | COMPOSITION AND METHODS FOR TREATING CANCER AND IMMUNE DISORDERS USING VEILLONELLA BACTERIA | July 2021 | December 2023 | Allow | 29 | 1 | 1 | No | No |
| 17367812 | IMMUNOGENIC COMPOSITIONS COMPRISING MYCOBACTERIUM TUBERCULOSIS POLYPEPTIDES AND FUSIONS THEREOF | July 2021 | September 2023 | Allow | 27 | 1 | 1 | Yes | No |
| 17346362 | MODIFIED MENINGOCOCCAL FHBP POLYPEPTIDES | June 2021 | July 2023 | Allow | 25 | 1 | 1 | No | No |
| 17331536 | VACCINE FOR IMMUNOCOMPROMISED HOSTS | May 2021 | July 2023 | Allow | 25 | 1 | 1 | Yes | No |
| 17324606 | Rapid Analysis of Cyanobacterial Toxins | May 2021 | November 2022 | Allow | 17 | 0 | 0 | No | No |
| 17243455 | NEUTRALIZING ANTIBODIES TO PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN AND THEIR USE | April 2021 | May 2023 | Allow | 25 | 1 | 1 | No | No |
| 17241494 | COMPOSITIONS AND METHODS FOR TREATING SECONDARY TUBERCULOSIS AND NONTUBERCULOUS MYCOBACTERIUM INFECTIONS | April 2021 | July 2024 | Abandon | 39 | 2 | 1 | Yes | No |
| 17275892 | ANTI-PARASITIC IMMUNOLOGICAL COMPOSITIONS | March 2021 | October 2023 | Allow | 31 | 2 | 1 | Yes | No |
| 17191490 | Recombinant Acinetobacter baumannii strain AB5075 | March 2021 | June 2024 | Abandon | 40 | 3 | 1 | No | No |
| 17175702 | MULTI-FUNCTIONAL BIOFERTILIZER | February 2021 | December 2024 | Abandon | 46 | 1 | 1 | No | No |
| 17266780 | COMPOSITION FOR BIOLOGICAL CONTROL OF PHYTONEMATODES | February 2021 | January 2025 | Abandon | 47 | 2 | 0 | No | No |
| 17265610 | MODIFIED MENINGOCOCCAL FHBP POLYPEPTIDES | February 2021 | March 2023 | Allow | 25 | 2 | 1 | Yes | No |
| 17264749 | METHOD FOR IMMUNOLOGICALLY DETECTING MYCOPLASMA PNEUMONIAE | January 2021 | October 2022 | Abandon | 21 | 1 | 1 | No | No |
| 17157787 | Method of Treating Cervical Vertigo | January 2021 | December 2023 | Abandon | 34 | 2 | 0 | No | No |
| 17151746 | ISOLATED POLYNUCLEOTIDE INCLUDING PROMOTER REGION, HOST CELL INCLUDING THE SAME AND METHOD OF EXPRESSING A TARGET GENE USING THE HOST CELL | January 2021 | June 2023 | Allow | 29 | 2 | 1 | No | No |
| 17141515 | CAMELIDAE SINGLE-DOMAIN ANTIBODIES AGAINST YERSINIA PESTIS AND METHODS OF USE | January 2021 | March 2024 | Allow | 38 | 3 | 1 | No | No |
| 17141501 | CAMELIDAE SINGLE-DOMAIN ANTIBODIES AGAINST YERSINIA PESTIS AND METHODS OF USE | January 2021 | January 2024 | Abandon | 36 | 2 | 1 | No | No |
| 17141477 | CAMELIDAE SINGLE-DOMAIN ANTIBODIES AGAINST YERSINIA PESTIS AND METHODS OF USE | January 2021 | January 2024 | Allow | 36 | 1 | 1 | No | No |
| 17141533 | CAMELIDAE SINGLE-DOMAIN ANTIBODIES AGAINST YERSINIA PESTIS AND METHODS OF USE | January 2021 | March 2024 | Allow | 38 | 3 | 1 | No | No |
| 17141566 | CAMELIDAE SINGLE-DOMAIN ANTIBODIES AGAINST YERSINIA PESTIS AND METHODS OF USE | January 2021 | September 2023 | Allow | 33 | 1 | 2 | No | No |
| 17141554 | CAMELIDAE SINGLE-DOMAIN ANTIBODIES AGAINST YERSINIA PESTIS AND METHODS OF USE | January 2021 | March 2024 | Allow | 38 | 3 | 1 | No | No |
| 17111115 | INSECTICIDAL POLYPEPTIDES HAVING IMPROVED ACTIVITY SPECTRUM AND USES THEREOF | December 2020 | January 2023 | Allow | 25 | 3 | 1 | Yes | No |
| 17103275 | SYNTHETIC PLASMODIUM ANTIGENS, COMPOSITIONS, AND USES THEREOF | November 2020 | June 2023 | Allow | 30 | 1 | 1 | No | No |
| 17095427 | COMPOSITIONS COMPRISING BACTERIAL STRAINS | November 2020 | July 2023 | Abandon | 32 | 2 | 1 | No | No |
| 16949235 | Pet Food Compositions Including Probiotics and Methods of Manufacture and Use Thereof | October 2020 | July 2022 | Allow | 21 | 1 | 0 | No | No |
| 17076616 | BIOMARKERS AND IMMUNOGENIC COMPOSITIONS FOR FILARIAL PARASITES | October 2020 | October 2024 | Allow | 48 | 4 | 1 | Yes | No |
| 16974113 | Method and apparatus to search for, find, collect and confirm the presence of ptentially dangerous airborne particles such as COVID-19 VIRUS | October 2020 | January 2023 | Abandon | 28 | 0 | 1 | No | No |
| 17029672 | BACILLUS COMPOSITIONS AND METHODS OF USE WITH RUMINANTS | September 2020 | July 2022 | Allow | 22 | 2 | 0 | No | No |
| 17024746 | Genetically Modified Nitrogen Fixing Bacteria and Uses Thereof | September 2020 | April 2025 | Allow | 55 | 2 | 0 | No | No |
| 17025706 | Enterococcus gallinarum flagellin polypeptides | September 2020 | July 2023 | Allow | 34 | 2 | 1 | No | No |
| 16979045 | USES OF CYANOBACTERIUM EXTRACELLULAR POLYMER, COMPOSITIONS, COATED SURFACES OR ARTICLES | September 2020 | February 2024 | Abandon | 41 | 0 | 1 | No | No |
| 16978870 | Antibodies to USPA2 | September 2020 | June 2024 | Allow | 45 | 4 | 1 | No | No |
| 16977692 | NANOVESICLES DERIVED FROM COPROCOCCUS SP. BACTERIA, AND USE THEREOF | September 2020 | August 2024 | Abandon | 48 | 1 | 1 | No | No |
| 17005961 | IMMUNOTHERAPIES EMPLOYING SELF-ASSEMBLING VACCINES | August 2020 | January 2023 | Abandon | 28 | 2 | 1 | Yes | No |
| 16997781 | CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO | August 2020 | June 2023 | Abandon | 34 | 2 | 1 | No | No |
| 16997484 | COMPOSITION | August 2020 | June 2024 | Abandon | 46 | 3 | 1 | Yes | No |
| 16968507 | COMBINATION OF A TETANUS TOXOID, ANTI-OX40 ANTIBODY AND/OR ANTI-PD-1 ANTIBODY TO TREAT TUMORS | August 2020 | March 2023 | Abandon | 31 | 2 | 1 | No | No |
| 16985589 | VACCINE COMPOSITION AGAINST STREPTOCOCCUS SUIS INFECTION | August 2020 | March 2024 | Allow | 43 | 4 | 1 | Yes | No |
| 16966853 | FECAL FUNGOME AND THERAPEUTIC EFFICACY OF FECAL MICROBIOTA TRANSPLANTATION | July 2020 | March 2023 | Abandon | 31 | 2 | 1 | Yes | No |
| 16943763 | ANTI-INFLAMMATORY COMPOUNDS AND METHODS OF USE | July 2020 | August 2021 | Allow | 13 | 1 | 1 | No | No |
| 16935899 | COMPOSITIONS AND METHODS FOR TREATING SKIN INFECTIONS AND OTHER DISEASES | July 2020 | January 2023 | Abandon | 29 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ZEMAN, ROBERT A.
With a 42.1% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 22.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ZEMAN, ROBERT A works in Art Unit 1645 and has examined 912 patent applications in our dataset. With an allowance rate of 50.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 37 months.
Examiner ZEMAN, ROBERT A's allowance rate of 50.7% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ZEMAN, ROBERT A receive 2.27 office actions before reaching final disposition. This places the examiner in the 77% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by ZEMAN, ROBERT A is 37 months. This places the examiner in the 13% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +30.8% benefit to allowance rate for applications examined by ZEMAN, ROBERT A. This interview benefit is in the 82% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 19.5% of applications are subsequently allowed. This success rate is in the 12% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 37.3% of cases where such amendments are filed. This entry rate is in the 49% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 41.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 37% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 74.0% of appeals filed. This is in the 58% percentile among all examiners. Of these withdrawals, 70.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 67.9% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 3.5% of allowed cases (in the 85% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 15.2% of allowed cases (in the 91% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.